Prednisone
B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1–Like
Explore 9 assets in B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1–Like →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05157971CT.gov Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT02420717CT.gov Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1–Like
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Prednisone (this asset) | City of Hope Medical Center | P2 | B · 60 |
| Mercaptopurine Anhydrous | City of Hope Medical Center | P2 | B |
| Cyclophosphamide | City of Hope Medical Center | P2 | B |
| Cytarabine | City of Hope Medical Center | P2 | B |
| Methotrexate | City of Hope Medical Center | P2 | B |
| Ruxolitinib Phosphate | M.D. Anderson Cancer Center | P2 | CCC |
| Adriamycin | M.D. Anderson Cancer Center | P2 | CCC |
| Dexasone | M.D. Anderson Cancer Center | P2 | CCC |
| Dasatinib | M.D. Anderson Cancer Center | P2 | CCC |
+8 more in the B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1–Like cohort
Other indications for Prednisone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 74 |
| Diffuse Large B-Cell Lymphoma | — | P4 | BBB · 74 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Prednisone in B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1–Like. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/prednisone-b-lymphoblastic-leukemialymphoma-bcr-abl1like
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →